Adam J. Townsend - 03 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Commercial Officer
Signature
/s/ David Watson, attorney-in-fact for Adam Townsend
Issuer symbol
APLS
Transactions as of
03 Jan 2023
Net transactions value
-$178,050
Form type
4
Filing time
05 Jan 2023, 19:00:50 UTC
Previous filing
07 Dec 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $75,450 +5,000 +12% $15.09 47,907 03 Jan 2023 Direct F1
transaction APLS Common Stock Sale $253,500 -5,000 -10% $50.70 42,907 03 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.6% $0.000000 302,500 03 Jan 2023 Common Stock 5,000 $15.09 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from an established 10b5-1 plan.
F2 This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.
F3 This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.